A new trading day began on Tuesday, with Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock price down -3.63% from the previous day of trading, before settling in for the closing price of $7.72. XERS’s price has ranged from $2.82 to $10.08 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 40.01% over the last five years. Meanwhile, its annual earnings per share averaged 92.23%. With a float of $155.66 million, this company’s outstanding shares have now reached $165.53 million.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc is 6.18%, while institutional ownership is 55.10%. The most recent insider transaction that took place on Sep 11 ’25, was worth 119,610. In this transaction Director of this company sold 15,500 shares at a rate of $7.72, taking the stock ownership to the 142,000 shares. Before that another transaction happened on Sep 11 ’25, when Company’s Director proposed sale 15,500 for $7.81, making the entire transaction worth $121,055.
Xeris Biopharma Holdings Inc (XERS) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.03 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 92.23% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Here are Xeris Biopharma Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.64. Likewise, its price to free cash flow for the trailing twelve months is 123.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.16 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Analysing the last 5-days average volume posted by the [Xeris Biopharma Holdings Inc, XERS], we can find that recorded value of 5.31 million was better than the volume posted last year of 2.52 million. As of the previous 9 days, the stock’s Stochastic %D was 17.21%.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 53.52%, which indicates a significant increase from 14.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.54 in the past 14 days, which was higher than the 0.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.38, while its 200-day Moving Average is $5.80. Now, the first resistance to watch is $7.70. This is followed by the second major resistance level at $7.97. The third major resistance level sits at $8.19. If the price goes on to break the first support level at $7.22, it is likely to go to the next support level at $7.00. Should the price break the second support level, the third support level stands at $6.73.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
With a market capitalization of 1.23 billion, the company has a total of 165,924K Shares Outstanding. Currently, annual sales are 203,070 K while annual income is -54,840 K. The company’s previous quarter sales were 74,380 K while its latest quarter income was 620 K.
